

**RECORDATI BOARD APPROVES THE 2023 ACCOUNTS,
CONFIRMING STRONG PRELIMINARY RESULTS:
REVENUE € 2,082.3M, EBITDA⁽¹⁾ € 769.6M, ADJUSTED NET INCOME⁽²⁾ € 524.6M
2023 PROPOSED DIVIDEND € 1.20 (+4.3%)**

- 2023 Financial Year Results confirm the strong preliminary figures announced on 22nd February 2024:
 - Net revenue € 2,082.3 million, +12.4% or +14.0% on a like-for-like⁽³⁾ basis at constant exchange rates (CER)
 - EBITDA⁽¹⁾ € 769.6 million, +14.4%, margin of 37.0%
 - Adjusted net income⁽²⁾ € 524.6 million, +10.8%
 - Net Income € 389.2 million, +24.6%
 - Free cash flow⁽⁴⁾ at € 456.0 million, + € 17.0 million versus prior year
 - Net debt⁽⁵⁾ at € 1,579.4 million, approximately 1.96x EBITDA (pro-forma)
 - Shareholders' equity at € 1,686.4 million
- Proposed dividend for 2023 € 1.20 per share, of which € 0.57 already paid
- 2023 consolidated non-financial statements and 2024 ESG objectives approved
- Ordinary Shareholders' Meeting convened for April 22, 2024 in a single call

Milan, 19th March 2024 – Recordati's Board of Directors approved the consolidated financial statements for the year 2023 as well as Recordati S.p.A.'s accounts and the 2023 corporate governance and ownership report as required by art. 123bis of the Consolidated Law on Financial Intermediation. The financial statements at, and for the year ended, 31st December 2023 and the aforesaid report as well as the reports issued by the independent external auditors and by the Board of Statutory Auditors will be made available, by 31st March, in compliance with the terms of the law, at the company's head office and published on the company's website www.recordati.com and can also be viewed on the authorized storage system 1Info (www.1Info.it). The Board of Directors also approved the consolidated non-financial statements, pursuant to Legislative Decree n. 254/2016, dated 31st December 2023 which will be made available in the same manner.

2023 consolidated financial results

The Board of Directors approved the consolidated financial statements for the year 2023, confirming the preliminary results published on 22nd February.

As previously announced, consolidated net revenue in 2023 reached € 2,082.3 million, +12.4% compared to 2022 or +14.0% on a like-for-like⁽³⁾ basis at CER (+9.6% excluding Türkiye), at the high end of the guidance range upgraded in May 2023. This was driven by strong business momentum across both business units, and includes net revenue of €25.6 million related to Avodart® and Combodart®/Duodart®, following the finalization of the commercial agreement with GSK and subsequent integration of activities in all key markets⁽⁶⁾.

EBITDA rose to € 769.6 million, up 14.4% over 2022, with a margin of 37.0%, reflecting the strong revenue growth and efficiency initiatives already initiated in previous years. Net Income at € 389.2, at 18.7% of net revenue, was up 24.6% over the previous year, driven by the strong operating performance and lower non-recurring expenses versus 2022. Adjusted Net Income⁽²⁾ reached € 524.6 million, growing

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office
VIA M. CIVITALI, 1
20148 MILAN, ITALY
TEL. +39 0248787.1
FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up
BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI
00748210150
TAX CODE/VAT NO. 00748210150

10.8% over last year, benefitting from both the positive operating performance and a lower tax rate.

Thanks to the excellent operating results and strong free cash flow⁽⁴⁾ of € 456.0 million, the Group's net debt⁽⁵⁾ as of 31st December was € 1,579.4 million, or leverage of approximately 1.96x EBITDA (pro-forma, assuming the contribution of Avodart® and Combodart®/Duodart® for 12 months).

Dividend

Based on the results obtained and consistent with the Company dividend policy, which remains unchanged, the Board of Directors has proposed a dividend to shareholders of € 0.63 per share, in full balance of the interim 2023 dividend of € 0.57, for all shares outstanding at the ex-dividend date of 20 May 2024, excluding treasury shares in the portfolio at that date, against presentation of coupon no. 33 with payment on 22 May 2024 and record date 21 May 2024. The proposed full 2023 dividend is therefore € 1.20 per share (€ 1.15 per share in 2022).

Renewed ESG commitment

The Board of Directors also approved the consolidated non-financial statements dated 31st December 2023 and the Group's ESG objectives.

Key objectives include a commitment to creating an even more responsible and inclusive work environment, continued development of new drugs and new indications to meet the needs of patients, particularly those affected by rare diseases, installing new renewable energy generation systems, and expanding ESG monitoring activities in our supply chain. As previously announced and as a further demonstration of the willingness to pursue a sustainable growth model, the achievement of key goals in Environmental Protection (installed renewable energy capacity) and Responsible Sourcing (supplier sustainability audits) was linked to the € 400 million credit line signed in May 2023 with a pool of international relationship banks.

Recordati's focus and efforts in driving the group's ESG strategy continues to be recognized in 2023 by the main ESG indices and ratings. The inclusion in the FTSE4GOOD Index series was reconfirmed alongside the "Platinum" rating by EcoVadis. MSCI ESG Research confirmed Recordati's A rating and the Group was rated C+ with "Prime" status by ISS ESG, awarded to companies with a leading sustainability performance in their industry. In addition, Recordati received a "Robust" ESG Assessment from Moody's Analytics and is included in the MIB ESG Index, promoted by Euronext and Borsa Italiana.

Notice of Ordinary Meeting and Documentation

The Board of Directors also resolved to convene an Ordinary Shareholders' Meeting on April 22, 2024 at 9:30 a.m. in a single call - in the manner expressly stated in the notice of meeting to which reference is made - with the following agenda:

1. Report of the Board of Directors; Report of the Board of Statutory Auditors; Financial Statements as of December 31, 2023; resolutions pertaining thereto:
 - a) Financial Statements as of December 31, 2023;
 - b) Allocation of profit for the year 2023.
2. Report on remuneration policy and compensation paid pursuant to Article 123-ter, paragraphs 3-bis and 6, of Legislative Decree No. 58 of February 24, 1998:
 - a) binding deliberation on the first section on remuneration policy;
 - b) non-binding resolution on the second section on compensation paid for the year 2023.
3. Proposal to authorize the purchase and disposal of treasury shares; related and consequent resolutions.

The full notice of call of the Shareholders' Meeting will be made available to the public today at the Company's registered office, on the Company's⁽⁷⁾ website as well as on the authorized storage mechanism 1Info (www.1Info.it).

It should be noted that Recordati⁽⁸⁾ has decided to avail itself of the option to provide that Shareholders' attendance at the Shareholders' Meeting be exclusively through the Appointed Representative pursuant to Article 135-undecies of Legislative Decree No. 58/98, without physical participation by the Shareholders. Information on attending by proxy is available in the Notice of Meeting to which reference is made.

As for the proposed renewal the authorisation to purchase and dispose of treasury shares until the Shareholders' Meeting that will approve the financial statements as of 31 December 2024, it should be noted that this proposal, as in previous years, fulfils multiple purposes:

- (i) fulfilling the obligations arising from the stock option and/or share-based plans (performance shares) already adopted by the Company and other incentive plans that may be approved in the future;
- (ii) supporting business initiatives, since the authorisation to purchase treasury stock, if granted, will allow transactions such as the sale, contribution and exchange of treasury stock in order to acquire stakes in companies and/or to reach agreements with strategic partners within the Group's expansion objectives;
- (iii) supporting Recordati's shares liquidity, in order to promote the regular performance of security trading operations and to avoid price fluctuations inconsistent with the market trends.

The maximum of number of shares available for purchase is 3,500,000 and, in any case, on the condition that, at any time, the total par value of the treasury shares held by the Company never exceeds one fifth of the share capital, also taking into account any shares owned by subsidiaries, for a potential maximum outlay of € 200,000,000, with a minimum price not less than the par value of one Recordati share (€

0.125) and a maximum price not greater than the average of the official stock exchange prices in the five sessions prior to the purchase, plus 5%. Purchases may be completed through the assignment of specific positions to specialised intermediaries and must be performed in compliance with applicable law and according to the practices permitted by Consob in line with the provisions of art. 13 of EU Regulation 596/2014, where applicable.

At 18 March 2024, the Company has 2,781,590 shares in treasury stock, which amounts to 1.3% of the current share capital.

Within the terms of current legal and regulatory provisions, the additional Directors' Reports supporting the Shareholders' Meeting agenda items and any additional documentation on those items will be made available on the Company website and on the authorised storage mechanism 1Info (www.1Info.it).

⁽¹⁾ *Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory according to IFRS 3.*

⁽²⁾ *Net income excluding the amortization and write-down of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory pursuant to IFRS 3, and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.*

⁽³⁾ *Pro-forma growth calculated adding Q1 2022 revenue of EUSA Pharma (RRD) and excluding FY 2023 revenue of Avodart® and Combodart®/Duodart®(SPC).*

⁽⁴⁾ *Operating cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from exercise of stock options.*

⁽⁵⁾ *Cash and cash equivalents, less bank debts and loans, which include the measurement at fair value of hedging derivatives.*

⁽⁶⁾ *Trademarks are owned by or licensed to the GSK group of companies. Transition to Recordati of commercialization of Avodart® and Combodart® / Duodart® has been effected in the following markets: Austria, Belgium, Czech R, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Poland, Portugal, Spain, Sweden, Switzerland, UK.*

⁽⁷⁾ <https://recordati.com/shareholder-information/>

⁽⁸⁾ *In accordance with the provisions of Article 106 of Decree Law No. 18/2020 ("Decreto Cura Italia") converted with amendments by Law No. 27 of April 24, 2020, as amended and supplemented*

Recordati (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their lives. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2023, Recordati employed over 4,450 people and consolidated revenue of € 2,082.3 million. For more information, please visit www.recordati.com

Investor Relations

Eugenio Litz
+44 7824 394 750
investorelations@recordati.it

Investor Relations

Lucia Abbatantuoni
+39 337 1025645
investorelations@recordati.it

Media Relations Brunswick:

Barbara Scalchi / Andrea Mormandi
+39 02 9288 6200
recordati@brunswickgroup.com

This document contains forward-looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast as a result of a variety of reasons, most of which are beyond the Recordati group's control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the activities of the Recordati Group, and, as such, it is not intended as a medical scientific indication or recommendation, or as advertising.

RECORDATI GROUP

Summary of consolidated results prepared in accordance with International Financial Reporting Standards (IFRS)
(thousands of €)

INCOME STATEMENT	2023	2022	Change %
NET REVENUE	2,082,331	1,853,307	12.4
Cost of sales	(659,707)	(566,737)	16.4
GROSS PROFIT	1,422,624	1,286,570	10.6
Selling expenses	(472,857)	(462,665)	2.2
Research and development expenses	(255,747)	(220,102)	16.2
General and administrative expenses	(128,253)	(109,493)	17.1
Other income/(expenses), net	(7,759)	(56,984)	(86.4)
OPERATING INCOME	558,008	437,326	27.6
Financial income/(expenses), net	(66,972)	(35,891)	86.6
PRE-TAX INCOME	491,036	401,435	22.3
Income taxes	(101,822)	(89,099)	14.3
NET INCOME	389,214	312,336	24.6
Adjusted gross profit ⁽¹⁾	1,481,571	1,336,381	10.9
Adjusted operating income ⁽²⁾	626,593	536,060	16.9
Adjusted net income ⁽³⁾	524,591	473,306	10.8
EBITDA ⁽⁴⁾	769,631	672,750	14.4
Net income attributable to:			
Equity holders of the Parent	389,214	312,336	24.6
Non-controlling interests	0	0	0.0
EARNINGS PER SHARE (euro)	2023	2022	Change %
Basic	€ 1.893	€ 1.519	24.6
Diluted	€ 1.861	€ 1.494	24.6

⁽¹⁾ Gross profit adjusted by the impact of non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory according to IFRS 3.

⁽²⁾ Net income before income taxes, financial income and expenses and non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory according to IFRS 3.

⁽³⁾ Net income excluding the amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory pursuant to IFRS 3, and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.

⁽⁴⁾ Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory according to IFRS 3.

COMPOSITION OF REVENUE	2023	2022	Change %
Total	2,082,331	1,853,307	12.4
Italy	317,144	277,322	14.4
International	1,765,187	1,575,985	12.0

Pending completion of independent and statutory audits.

RECORDATI GROUP
 (€ thousands)
 Reconciliation of Net income to EBITDA⁽¹⁾

	2023	2022
Net income	389,214	312,336
Income taxes	101,822	89,099
Financial income/(expenses), net	66,972	35,891
Non-recurring operating expenses	9,638	48,923
Non-cash charges from PPA inventory uplift	58,947	49,811
Adjusted operating income⁽²⁾	626,593	536,060
Amortization and write-downs	143,038	136,690
EBITDA⁽¹⁾	769,631	672,750

⁽¹⁾ Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory according to IFRS 3.

⁽²⁾ Net income before income taxes, financial income and expenses and non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory according to IFRS 3.

Reconciliation of Net income to Adjusted Net income⁽¹⁾

	2023	2022
Net income	389,214	312,336
Amortization and write-downs of intangible assets (excluding software) and goodwill	112,227	107,415
Tax effect	(24,341)	(20,209)
Non-recurring operating expenses	9,638	48,923
Tax effect	(2,433)	(12,984)
Non-cash charges from PPA inventory uplift	58,947	49,811
Tax effect	(14,749)	(9,781)
Monetary net (gain)/losses from hyperinflation	(1,546)	(4,506)
Tax effect	371	2,301
Non-recurring tax income	(2,737)	0
Adjusted net income⁽¹⁾	524,591	473,306

⁽¹⁾ Net income excluding the amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory pursuant to IFRS 3, and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.

Pending completion of independent and statutory audits.

RECORDATI GROUP

Summary of consolidated results prepared in accordance with International Financial Reporting Standards (IFRS)
(thousands of €)

ASSETS	31.12.2023	31.12.2022
Property, plant and equipment	178,657	159,184
Intangible assets	1,938,197	1,758,173
Goodwill	778,350	780,057
Other equity investments and securities	21,555	28,871
Other non-current assets	12,458	9,556
Deferred tax assets	76,674	76,895
TOTAL NON-CURRENT ASSETS	3,005,891	2,812,736
Inventories	404,831	424,080
Trade receivables	445,193	361,898
Other receivables	99,401	63,915
Other current assets	19,924	15,387
Derivative instruments measured at fair value	11,079	23,603
Cash and cash equivalents	221,812	284,734
TOTAL CURRENT ASSETS	1,202,240	1,173,617
Non-current assets held for sale	0	12,470
TOTAL ASSETS	4,208,131	3,998,823

Pending completion of independent and statutory audits.

RECORDATI GROUP

Summary of consolidated results prepared in accordance with International Financial Reporting Standards (IFRS)
(thousands of €)

EQUITY AND LIABILITIES	31.12.2023	31.12.2022
Share capital	26,141	26,141
Share premium reserve	83,719	83,719
Treasury shares	(127,970)	(149,559)
Reserve for derivative instruments	(286)	5,249
Translation reserve	(264,700)	(205,018)
Other reserves	61,219	62,260
Profits carried forward	1,636,451	1,524,099
Net income	389,214	312,336
Interim dividend	(117,396)	(112,979)
Shareholders' equity attributable to equity holders of the Parent	1,686,392	1,546,248
Shareholders' equity attributable to non-controlling interests	0	0
TOTAL SHAREHOLDERS' EQUITY	1,686,392	1,546,248
Loans - due after one year	1,353,216	1,341,549
Provisions for employee benefits	21,239	19,418
Deferred tax liabilities	144,208	167,865
TOTAL NON-CURRENT LIABILITIES	1,518,663	1,528,832
Trade payables	263,979	224,703
Other payables	174,407	251,136
Tax liabilities	67,110	33,615
Other current liabilities	5,307	5,740
Provisions for risks and charges	16,596	16,209
Derivative instruments measured at fair value	19,993	17,369
Loans - due within one year	355,752	291,546
Short-term debts to banks and other lenders	99,932	83,425
TOTAL CURRENT LIABILITIES	1,003,076	923,743
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	4,208,131	3,998,823

Pending completion of independent and statutory audits.

RECORDATI GROUP

Summary of consolidated results prepared in accordance with International Financial Reporting Standards (IFRS)
(thousands of €)

CASH FLOW	2023	2022
OPERATING ACTIVITIES		
Net income	389,214	312,336
Income taxes	101,822	89,101
Net interest	67,879	30,679
Depreciation of property, plant and equipment	28,875	27,289
Amortization of intangible assets	113,795	98,467
Write-downs	368	10,934
Equity-settled share-based payment transactions	10,870	8,251
Other non-monetary components	61,970	70,751
Change in other assets and other liabilities	(8,211)	(16,811)
Cash flow generated/(used) by operating activities before change in working capital	766,582	630,997
Change in:		
- inventories	(50,337)	(65,801)
- trade receivables	(100,565)	(21,175)
- trade payables	40,269	25,589
Change in working capital	(110,633)	(61,387)
Interest received	5,103	1,938
Interest paid	(70,339)	(20,093)
Income taxes paid	(105,394)	(89,764)
Cash flow generated/(used) by operating activities	485,319	461,691
INVESTMENT ACTIVITIES		
Investments in property, plant and equipment	(29,687)	(23,887)
Disposals of property, plant and equipment	329	1,156
Investments in intangible assets	(353,577)	(72,452)
Disposals of intangible assets	317	1,318
Acquisition of holdings in subsidiaries	0	(673,259)
Sale of non-current assets held for sale	3,000	0
Cash flow generated/(used) by investment activities	(379,618)	(767,124)
FINANCING ACTIVITIES		
Opening of loans	347,611	1,356,970
Repayment of loans	(280,234)	(803,543)
Payment of lease liabilities	(10,172)	(10,225)
Change in short-term debts to banks and other lenders	12,452	67,296
Dividends paid	(245,958)	(230,602)
Purchase of treasury shares	(22,710)	(52,267)
Sale of treasury shares	30,097	13,648
Cash flow generated/(used) by financing activities	(168,914)	341,277
Change in cash and cash equivalents	(63,213)	35,844
Opening cash and cash equivalents	284,734	244,578
Currency translation effect	291	4,312
Closing cash and cash equivalents	221,812	284,734

Pending completion of independent and statutory audits.

RECORDATI S.P.A.

Summary of results prepared in accordance with International Financial Reporting Standards (IFRS)
(thousands of €)

	2023	2022	Change %
Revenue	554,021	512,310	8.1
Operating income	118,864	109,521	8.5
Pre-tax income	222,297	233,534	(4.8)
Net income	224,017	219,234	2.2

	31.12.2023	31.12.2022
Non-current assets	2,551,152	2,395,113
Current assets	455,144	424,456
TOTAL ASSETS	3,006,296	2,819,569
Shareholders' equity	352,782	362,987
Non-current liabilities	1,366,466	1,283,440
Current liabilities	1,287,048	1,173,142
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	3,006,296	2,819,569

Pending completion of independent and statutory audits.

Declaration by the Manager responsible for preparing the company's financial reports

The manager responsible for preparing the company's financial reports, Luigi La Corte, declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance, that the accounting information contained in this press release corresponds to the documentation evidence, books and accounting records.